Spinogenix Supports FRAXA Foundation in Pioneering Trial Against Fragile X Syndrome Spinogenix announces collaboration with FRAXA Research Foundation to advance Phase 2b trial of SPG601, aimed at treating Fragile X Syndrome.

Spinogenix Supports FRAXA Foundation in Pioneering Trial Against Fragile X Syndrome #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

Spinogenix Makes Significant Strides with Phase 2a Trial Results for Groundbreaking Fragile X Treatment at AACAP Spinogenix reveals full Phase 2a trial results for SPG601, a pioneering treatment for Fragile X Syndrome, showcasing promising cognitive improvements.

Spinogenix Makes Significant Strides with Phase 2a Trial Results for Groundbreaking Fragile X Treatment at AACAP #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601

Spinogenix Receives FDA Approval for SPG601 in Fragile X Syndrome Treatment Spinogenix has achieved a significant milestone with the FDA's support for SPG601, a pioneering treatment for Fragile X syndrome, addressing crucial needs in patient care.

Spinogenix Receives FDA Approval for SPG601 in Fragile X Syndrome Treatment #USA #Los_Angeles #Spinogenix #SPG601 #Fragile_X

Spinogenix's SPG601 Receives Orphan Drug Designation for Fragile X Syndrome Treatment Spinogenix's SPG601 has been granted orphan drug designation by the EMA for treating Fragile X Syndrome, marking a significant step in therapies for this condition.

Spinogenix's SPG601 Receives Orphan Drug Designation for Fragile X Syndrome Treatment #USA #Los_Angeles #Spinogenix #SPG601 #Fragile_X

Spinogenix Advances to Phase 2 Study Completion for SPG601 Targeting Fragile X Syndrome Spinogenix announces promising results from its Phase 2 study of SPG601 for treating Fragile X syndrome, showing potential to improve quality of life.

Spinogenix Advances to Phase 2 Study Completion for SPG601 Targeting Fragile X Syndrome #USA #Los_Angeles #Spinogenix #Fragile_X_Syndrome #SPG601